ValuEngine Downgrades Axovant Sciences (AXON) to Strong Sell

Axovant Sciences (NASDAQ:AXON) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a report released on Monday.

AXON has been the subject of a number of other reports. Cowen downgraded shares of Axovant Sciences from an “outperform” rating to a “market perform” rating in a research report on Friday, January 12th. Jefferies Group downgraded shares of Axovant Sciences from a “buy” rating to a “hold” rating and set a $6.00 price target for the company. in a research report on Thursday, December 21st. Zacks Investment Research downgraded shares of Axovant Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, February 14th. Chardan Capital upgraded shares of Axovant Sciences from a “sell” rating to a “neutral” rating and set a $2.50 price target for the company in a research report on Wednesday, January 10th. Finally, Oppenheimer reiterated a “hold” rating on shares of Axovant Sciences in a research report on Tuesday, February 13th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $13.61.

Shares of NASDAQ AXON traded down $0.10 during midday trading on Monday, reaching $1.23. The company’s stock had a trading volume of 858,223 shares, compared to its average volume of 1,488,679. The company has a current ratio of 4.58, a quick ratio of 4.58 and a debt-to-equity ratio of 0.45. Axovant Sciences has a fifty-two week low of $1.22 and a fifty-two week high of $27.98. The company has a market cap of $143.36, a price-to-earnings ratio of -0.68 and a beta of -0.40.

In other news, Director George Bickerstaff acquired 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 27th. The shares were acquired at an average cost of $1.50 per share, with a total value of $37,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 72.40% of the company’s stock.

A number of large investors have recently made changes to their positions in the stock. Millennium Management LLC increased its stake in Axovant Sciences by 445.0% in the fourth quarter. Millennium Management LLC now owns 482,964 shares of the biotechnology company’s stock valued at $2,545,000 after acquiring an additional 622,964 shares during the last quarter. TIAA CREF Investment Management LLC grew its stake in shares of Axovant Sciences by 52.6% during the fourth quarter. TIAA CREF Investment Management LLC now owns 183,129 shares of the biotechnology company’s stock worth $965,000 after buying an additional 63,162 shares during the last quarter. Two Sigma Investments LP bought a new stake in shares of Axovant Sciences during the fourth quarter worth $827,000. Goldman Sachs Group Inc. grew its stake in shares of Axovant Sciences by 284.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 182,676 shares of the biotechnology company’s stock worth $963,000 after buying an additional 135,141 shares during the last quarter. Finally, Deutsche Bank AG grew its stake in shares of Axovant Sciences by 7.0% during the fourth quarter. Deutsche Bank AG now owns 548,728 shares of the biotechnology company’s stock worth $2,891,000 after buying an additional 35,878 shares during the last quarter. 93.04% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “ValuEngine Downgrades Axovant Sciences (AXON) to Strong Sell” was published by WKRB News and is the property of of WKRB News. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.wkrb13.com/2018/04/03/valuengine-downgrades-axovant-sciences-axon-to-strong-sell.html.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply